文献速递乳腺技术与安全MR

COVID-19疫苗接种后MRI检出腋窝淋巴结病的频率与转归

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination.
PubMed 文献 · Eur Radiol · 2022-03-05

本回顾性队列研究纳入2021年1月22日至3月21日接种COVID-19疫苗后行乳腺MRI的357例患者,评估同侧腋窝淋巴结病的频率、转归及相关变量。乳腺MRI上淋巴结病频率为29%(104/357例),年轻患者和距第二剂疫苗时间间隔较短与淋巴结病发生显著相关(两者p=0.002)。多数淋巴结病在随访中消退或缩小,11%的患者在第二剂疫苗后持续长达64天;3例诊断为转移性腋窝癌,均有当前同侧乳腺癌诊断。

要点

  • 接种COVID-19疫苗后乳腺MRI检出同侧腋窝淋巴结病频率为29%(104/357例),多为良性发现。
  • 年轻患者及距第二剂疫苗时间间隔较短与淋巴结病发生显著相关(两者p=0.002)。
  • 淋巴结病可在第二剂疫苗后持续4-8周,11%的患者持续长达64天;当前同侧乳腺癌患者需警惕转移。

核心结论

  • 疫苗相关淋巴结病是COVID-19疫苗接种后的常见事件;短期随访是合适的临床方法,但当前同侧乳腺癌患者除外。淋巴结病可能在第二剂疫苗后持续4-8周,因此倾向于更长的随访期。

研究设计与样本

  • 回顾性队列研究,纳入2021年1月22日至2021年3月21日接种COVID-19疫苗后行乳腺MRI的患者357例,评估同侧腋窝淋巴结病的频率、相关变量及转归。

关键影像表现/征象

  • 乳腺MRI上同侧腋窝淋巴结病的频率为29%(104/357例)。
  • 多数淋巴结病在随访中消退或缩小,11%的患者在第二剂疫苗后持续长达64天。
  • 3例诊断为转移性腋窝癌,均有当前同侧乳腺癌诊断。

临床应用与阅片要点

  • 疫苗相关淋巴结病是COVID-19疫苗接种后的常见事件,短期随访是合适的临床方法,但当前同侧乳腺癌患者除外。
  • 淋巴结病可能在第二剂疫苗后持续4-8周,因此倾向于更长的随访期。
  • 当前同侧乳腺癌患者中,腋窝淋巴结病可能代表转移性癌,随访不合适。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the frequency of ipsilateral axillary adenopathy on breast MRI after COVID-19 vaccination. To investigate the duration, outcomes, and associated variables of vaccine-related adenopathy.

METHODS: In this retrospective cohort study, our database was queried for patients who underwent breast MRI following COVID-19 vaccination from January 22, 2021, to March 21, 2021. The frequency of ipsilateral axillary adenopathy and possible associated variables were evaluated, including age, personal history of ipsilateral breast cancer, clinical indication for breast MRI, type of vaccine, side of vaccination, number of doses, and number of days between the vaccine and the MRI exam. The outcomes of the adenopathy were investigated, including the duration of adenopathy and biopsy results.

RESULTS: A total of 357 patients were included. The frequency of adenopathy on breast MRI was 29% (104/357 patients). Younger patients and shorter time intervals from the second dose of the vaccine were significantly associated with the development of adenopathy (p = 0.002 for both). Most adenopathy resolved or decreased on follow-up, with 11% of patients presenting persistence of adenopathy up to 64 days after the second dose of the vaccine. Metastatic axillary carcinoma was diagnosed in three patients; all three had a current ipsilateral breast cancer diagnosis.

CONCLUSIONS: Vaccine-related adenopathy is a frequent event after COVID-19 vaccination; short-term follow-up is an appropriate clinical approach, except in patients with current ipsilateral breast cancer. Adenopathy may often persist 4-8 weeks after the second dose of the vaccine, thus favoring longer follow-up periods.

KEY POINTS: • MRI-detected ipsilateral axillary adenopathy is a frequent benign finding after mRNA COVID-19 vaccination. • Axillary adenopathy following COVID-19 vaccination often persists > 4 weeks after vaccination, favoring longer follow-up periods. • In patients with concurrent ipsilateral breast cancer, axillary adenopathy can represent metastatic carcinoma and follow-up is not appropriate.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Horvat, Sevilimedu, Becker, et al. Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination. Eur Radiol. 2022. PMID: 35247087. doi:10.1007/s00330-022-08655-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。